NCT06246136Recruiting
Comparative Effectiveness and Safety of ELIOS in Patients With Open-Angle Glaucoma Undergoing Cataract Surgery
A Prospective, Multicenter, Randomized Clinical Trial to Evaluate the Safety and Effectiveness of ELIOS vs Competitor in Patients With Open-Angle Glaucoma Undergoing Cataract Surgery
Source: ClinicalTrials.gov · Last updated 17 Jun 2026
Brief summary (registry, in English)
The primary study objective is to compare the effectiveness of the combination of phacoemulsification with intraocular lens implant with ELIOS or competitor device in reducing IOP at 12 months postoperatively.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 194 (estimated)
- First submitted
- 30 Jan 2024
- Start date
- 5 Dec 2023
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Elios Vision, Inc.
- Diseases
- Glaucoma
- NCT number
- NCT06246136
What you commit to
- Study type: Interventional
- Planned participants: 194
- From 5 Dec 2023 to the primary completion date, 31 Dec 2027
- 16 sites in 6 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior incisional glaucoma surgery, intraocular surgery or ocular laser treatment of any type with the exception of selective laser trabeculoplasty (SLT) occurring a minimum of 6 months prior to the Screening visit
Other illness
- Secondary glaucoma, including traumatic, neovascular, uveitic, lens-induced, steroid-induced, angle-recession, glaucoma associated with vascular disorders, and glaucoma associated with increased episcleral venous pressure
Other
- All forms of angle closure glaucoma
- Congenital or developmental glaucoma
Who the study is looking for
- Male or female subjects.
- 40 years old or older.
- Diagnosis of mild to moderate primary open-angle glaucoma, pseudoexfoliation glaucoma or pigmentary glaucoma:
- Visually significant cataract eligible for phacoemulsification.
Age in the registry: 40 years to - · Sex: All · Does not accept healthy volunteers
Sites (16)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| ELIOS Clinical Site Coordinator of this site? Confirm its status | Leuven | Belgium | Recruiting |
| ELIOS Clinical Site Coordinator of this site? Confirm its status | Bochum | Germany | Recruiting |
| Elios clinical site Coordinator of this site? Confirm its status | Bonn | Germany | Recruiting |
| ELIOS clinical site Coordinator of this site? Confirm its status | Heidelberg | Germany | Recruiting |
| ELIOS clinical site Coordinator of this site? Confirm its status | Barcelona | Spain | Recruiting |
| ELIOS Clinical site Coordinator of this site? Confirm its status | Madrid | Spain | Recruiting |
| ELIOS Clincal Site Coordinator of this site? Confirm its status | Madrid | Spain | Recruiting |
| Elios Clinical Site Coordinator of this site? Confirm its status | Avranches | France | Recruiting |
| ELIOS Clinical Site Coordinator of this site? Confirm its status | Bordeaux | France | Recruiting |
| ELIOS clinical site Coordinator of this site? Confirm its status | Paris | France | Recruiting |
| ELIOS Clinical Site Coordinator of this site? Confirm its status | East Grinstead | United Kingdom | Recruiting |
| ELIOS Clinical Site Coordinator of this site? Confirm its status | Edinburgh | United Kingdom | Recruiting |
| ELIOS Clinical Site Coordinator of this site? Confirm its status | Guildford | United Kingdom | Recruiting |
| ELIOS clinical site Coordinator of this site? Confirm its status | London | United Kingdom | Recruiting |
| ELIOS Clinical Site Coordinator of this site? Confirm its status | Manchester | United Kingdom | Recruiting |
| ELIOS Clinical Site Coordinator of this site? Confirm its status | Maastricht | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.